AngioDynamics Stock Is Falling Thursday: What's Going On?

AngioDynamics shares fell 21.46% to $11.14 despite Q1 adjusted loss of $0.04 per share versus the $0.11 consensus loss and revenue of $80.915 million versus $80.50 million expected. Fiscal 2027 guidance was reaffirmed at revenue of $336 million-$341 million and an adjusted loss of $0.24-$0.29 per share; the company also named Eric Honroth CEO effective Nov. 2. Separately, the FDA cleared a 40-patient NanoKnife feasibility study for benign prostatic hyperplasia.

Analysis

The selloff suggests investors are discounting the quality and durability of growth, not rewarding a modest quarterly beat. The key vulnerability is the gap between faster-growing product lines and the company’s full-year revenue outlook: the guidance range is close to expectations, so continued execution—not the reported beat—is needed to support the growth case. Mechanical thrombectomy’s mixed product trends also make aggregate growth less informative; management’s “normalize” framing for AngioVac should be tested against subsequent sequential sales rather than taken as proof of a rebound.

The cash balance and debt-free position reduce near-term financing risk, but do not establish how long the company can fund losses without improved economics. Verify operating cash burn, gross-margin trajectory, and segment/product contribution before treating the balance sheet as a durable floor. The CEO transition adds execution uncertainty around commercial priorities and guidance ownership. The RELIEF study is longer-dated optionality, not a near-term revenue catalyst: a 40-patient feasibility trial with a six-month endpoint would need positive results and further development before changing the earnings outlook.

Contrarian angle: the drawdown may over-penalize a single weak AngioVac comparison if AlphaVac and NanoKnife momentum persists. But the better-than-expected quarter alone is not a reversal signal. Over days, price stabilization matters; over 1–3 months, product-level sales and guidance commentary matter most; over 6–18 months, clinical evidence and commercial adoption determine whether growth can translate into sustainable economics.

Key Decisions for Investors

• Do not chase a short after the 21% one-day decline. Treat ANGO as a watchlist name until trading stabilizes and the next update clarifies product-level demand; the risk/reward is unattractive if the selloff has already reset expectations.
• Avoid dip-buying solely on the earnings beat. Consider a starter long only if subsequent reporting shows continued AlphaVac/NanoKnife momentum, AngioVac stabilizing sequentially, and no deterioration in full-year guidance; those conditions would support the view that the reaction overshot fundamentals.
• Set a downside alert for any guidance reduction or evidence that operating cash burn is accelerating, and an upside alert for a sustained AngioVac recovery alongside continued growth in newer product lines. These are more useful thesis tests than the headline adjusted loss beat.
• Keep the RELIEF study out of near-term earnings models; revisit the opportunity after enrollment and six-month symptom data are available. Falsification of the longer-term optionality case would be weak study outcomes or failure to advance the technology beyond feasibility testing.